Document is current

Any future updates will be listed below

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

Crossref DOI link: https://doi.org/10.1186/s12885-015-1656-4

Published Online: 2015-10-06

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark